Short answer
EyePoint, Inc. (EYPT) filed an 8-K current report with the SEC on April 13, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Updated investor presentation posted April 13, 2026.
EyePoint, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Updated investor presentation posted April 13, 2026
- Exhibit 99.1 contains the substantive investor materials
- Potentially material updates to EyePoint’s pipeline, clinical programs, or corporate outlookிழமை
Item EX-99.1 · Exhibit EX-99.1
- DURAVYU Phase 3 wet AMD topline data expected mid-2026, creating a near-term clinical catalyst
- Phase 3 DME trials COMO and CAPRI targeting full enrollment in 3Q 2026, expanding development into a $15B+ combined market
- ~$220M+ cash and investments supports runway into Q4 2027, reducing near-term financing pressure
- Prior data showed treatment-burden reductions up to 89% and no DURAVYU-related serious adverse events across 190+ patients
- Key risks remain regulatory approval, clinical readouts, manufacturing scale-up, FDA warning-letter matters and August 2022 subpoena uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other EyePoint, Inc. 8-K filings
Get the next EYPT 8-K as it lands
Follow EYPT for push alerts, or ask the research agent what this filing means.